CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 4, 2012, Pages 586-592

  Liu, Ping ^a   Sun, Yu Lei ^b   Du, Jie ^a   Hou, Xiao Sai ^a   Meng, Hua ^c  

^a INNER MONGOLIA MEDICAL COLLEGE   (China)

^b PLASTIC SURGERY HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

CD105; Clinicopathology; Epithelial ovarian cancer; Ki67; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOGLIN; KI 67 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863680774     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31823c36b8     Document Type: Article

References (27)

1. Li YL, Ye F, Cheng XD, et al. Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer. Eur J Cancer. 2010;46:2104-2018.
2. Wang C, Weng Y, Wang H, et al. Relationship between the expression of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase and survival in epithelial ovarian cancer. J Huazhong Univ Sci Technol Med Sci. 2010;30:494-499.
3. Chauhan SC, Singh AP, Ruiz F, et al. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol. 2006;19:1386-1394.
4. Annunziata CM, Stavnes HT, Kleinberg L, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116:3276-3284.
5. Gromova P, Rubin BP, Thys A, et al. ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumors [published online ahead of print March 24, 2011]. J Cell Mol Med. doi: 10.1111/j.1582-4934. 2011.01315.x.
6. Wood LM, Pan ZK, Guirnalda P, et al. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Cancer Immunol Immunother. 2011;60:931-942.
7. Zhang Y, Yang Y, Hong H, et al. Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med. 2011;4:32-42.
8. Davidson B, Stavnes HT, FLrsund M, et al. CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival. Breast. 2010;19:493-498.
9. Zijlmans HJ, Fleuren GJ, Hazelbag S, et al. Expression of endoglin (CD105) in cervical cancer. Br J Cancer. 2009;100:1617-1626.
10. Medetoglu B, Gunluoglu MZ, Demir A, et al. Tumor angiogenesis in predicting the survival of patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2010;140:996-1000.
11. Bozas G, Terpos E, Gika D, et al. Prechemotherapy serum levels of CD105, transforming growth factor beta2, and vascular endothelial growth factor are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy. Int J Gynecol Cancer. 2010;20:248-254.
12. Ren SX, Ren ZJ, Zhao MY, et al. Antitumor activity of endogenous mFlt4 displayed on a T4 phage nanoparticle surface. Acta Pharmacol Sin. 2009;30:637-645.
13. Romero Q, Bendahl PO, Klintman M, et al. Ki67 proliferation in core biopsies versus surgical samples: a model for neoadjuvant breast cancer studies. BMC Cancer. 2011;11:341.
14. Zhu C, Luo J, Shi H, et al. Expression of tubulin, p53, ki67, receptors for estrogen, and progesterone in endometrial cancer. Eur J Gynaecol Oncol. 2009;30:514-517.
15. Santisteban M, Reynolds C, Barr Fritcher EG, et al. Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat. 2010;121:431-437.
16. Zellweger T, Günther S, Zlobec I, et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer. 2009;124:2116-2123.
17. Penault-Llorca F, André F, Sagan C, et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27:2809-2815.
18. Goff BA, Ries JA, Els LP, et al. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol. 1998;70:378-385.
19. Adams SF, Levine DA, Cadungog MG, et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer. 2009;115:2891-2902.
20. Creasman WT. Announcements: FIGO stages: 1988 revision. Gynecol Oncol. 1989;35:125-127.
21. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer. 1998;82:893-901.
22. Saad RS, Liu YL, Nathan G, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 2004;17:197-203.
23. Duff SE, Li C, Garland JM, et al. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003;17:984-992.
24. Yang LY, Lu WQ, Huang GW, et al. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer. 2006;6:110.
25. Pérez-Gómez E, Del Castillo G, Juan Francisco S, et al. The role of the TGF-A coreceptor endoglin in cancer. Scientific World J. 2010;10:2367-2384.
26. Taskiran C, Erdem O, Onan A, et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer. 2006;16:1789-1793.
27. Bock AJ, Tuft Stavnes H, Ksrn J, et al. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Tumour Biol. 2011;32:589-596.